Italian Design Brands Eyeing Acquisitions
Italian Design Brands said it is in talks with many potential acquisitions as it reports strong growth in 2023.
Source: wwd.com
📰 Frank Jiang News
Frank Jiang News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Frank Jiang. Real-time updates on events, politics, business and more.
Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for NextGeneration Selective PARP1 Inhibitor and AntibodyDrug Conjugate
Merck a leading science and technology company today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. Hengrui.
United States Hengrui Pharma Frank Jiang Hengrui Claudin Global Head Of Research Development Jiangsu Hengrui Pharmaceuticals Co
Source: businesswireindia.com
Italian Design Brands to Open First U.S. Flagship
Italian Design Brands, home to Meridiani and Davide Groppi, reveals its U.S. growth strategy as it opens its first U.S. flagship in New York City.
Source: wwd.com
Italian Design Brands Takes Majority Stake In Turri, Axolight – WWD
Italian Design Brands expands its portfolio with majority stakes in two upscale Italian companies Turri and Axolight.
Source: wwd.com
AIA Design Awards 2022 - Hawaii Business Magazine
Shaping communities through design excellence — All of the awardees exemplified a vision to meet or exceed safety requirements, utilize sustainable and efficient methods, and fulfill our cultural and emotional needs.
University Of Hawaii At Manoa United States Turtle Bay Mauna Kea Solomon Elementary School Punahou School
Source: hawaiibusiness.com
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose...
Long Wu Jason Yang Jean Christophe Pointeau Frank Jiang Pfizer Inc Prnewswire Cstone Pharmaceuticals
Source: prnewswire.com
China's NMPA approves CStone's sugemalimab for NSCLC treatment
China’s National Medical Products Administration (NMPA) has approved CStone’s sugemalimab (Cejemly) for unresectable stage III NSCLC treatment.
CStone Pharmaceuticals Reports 2021 Annual Results and Recent Business Highlights
SUZHOU, China, June 1, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2021 full-year financial results and recent business highlights. Dr. Frank Jiang, CEO of CStone, commented, "As a full-fledged biopharmaceutical company, we achieved significant milestones in 2021. As of...
United States Hong Kong Frank Jiang National Pathology Quality Control Center American Society For Clinical Oncology Research Development
Source: asiaone.com
New drug application for treatment of thyroid cancer
CStone Pharmaceuticals today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental new drug
Source: eturbonews.com
15 Great Chinese Dramas to Binge
There's really no excuse to miss out on C-dramas' epic fight scenes and time travel romances—especially since you can find a lot on YouTube or for free.
Source: wired.com